10-Q: Aeternum Health Completes Merger, Shifts Focus to Mining and Longevity

Aeternum Health, Inc. (formerly Shorepower Technologies Inc.) has completed a merger with Aeternum Health LLC, divesting its transportation electrification business to focus on critical mineral mining and longevity-focused healthcare, reporting a significant gain from discontinued operations but also substantial ongoing operational losses.

Summary

• Aeternum Health, Inc. (formerly Shorepower Technologies Inc.) has completed a merger with Aeternum Health LLC, effective June 30, 2026, and has divested its legacy transportation electrification business.
• The company is now focused on critical mineral mining and longevity-focused healthcare, including healthspan optimization and peptide-based therapies.
• For the six months ended June 30, 2026, the company reported a net income of $1,582,883, largely due to a gain of $2,037,315 from the disposal of its discontinued business.
• However, the company incurred a loss from continuing operations of $300,879 for the same period, with no revenue generated from these new operations.
• As of June 30, 2026, the company has cash of $702,809 and working capital of approximately $1.8 million, but also an accumulated deficit of approximately $1.7 million.
• Management has stated that substantial doubt exists about the company's ability to continue as a going concern, dependent on obtaining additional financing and successfully executing its new business plan.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant accumulated deficits, ongoing operational losses from continuing operations, and substantial doubt about the company's ability to continue as a going concern, despite a recent strategic pivot and a large gain from discontinued operations.

Positives

• Successful completion of the merger with Aeternum Health LLC, marking a strategic pivot.
• Significant gain of $2,037,315 from the disposal of the legacy transportation electrification business.
• Increased cash balance to $702,809 as of June 30, 2026, with working capital of approximately $1.8 million.
• New strategic focus on high-growth sectors: critical mineral mining and longevity-focused healthcare.
• Secured $2.17 million in loans from related parties to fund operations during the first half of 2026.
• The company has established a new subsidiary in South Africa (Aeternum SA (Pty) Ltd) and the Cayman Islands (Aeternum Cayman Islands Ltd) to support its new ventures.

Negatives

• The company generated no revenue from continuing operations for the six months ended June 30, 2026.
• Incurred a loss from continuing operations of $300,879 for the six months ended June 30, 2026.
• An accumulated deficit of $1,735,606 as of June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Disclosure controls and procedures were not effective as of June 30, 2026.
• The company has no revenue from continuing operations and expects to incur additional expenditures for exploration and development.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing, successfully executing its business plan, and ultimately generating sufficient revenues and cash flows from operations.
• There can be no assurance that additional financing will be available when needed or on terms acceptable to the Company.
• The investment in American Renaissance Minerals LLC ($10.0 million for a 50.1% interest) is subject to various closing conditions, including obtaining a new mining permit and evidence of U.S. government financing.
• The agreement to invest in ARM can be terminated if the transaction has not closed by December 31, 2026.
• Exploration and development activities are subject to significant uncertainties, including obtaining necessary permits and financing, establishing economically recoverable mineral reserves, and developing commercially viable mining operations.
• The company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Future Outlook

The company is in the early stages of developing its new business operations in critical mineral mining and longevity-focused healthcare. It expects to incur additional costs related to exploration, development, and other planned business activities and will require additional capital to fund these activities. Management intends to seek additional funding through debt and equity financings, related-party funding, and other potential sources. The company has agreed to invest $10.0 million in American Renaissance Minerals LLC, subject to closing conditions.

Management Comments

• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives.
• Management has evaluated the effectiveness of the registrants disclosure controls and procedures and concluded they were not effective as of June 30, 2026.
• Management intends to seek additional funding through debt and equity financings, related-party funding and other potential sources of capital.

Industry Context

StockSavvy.ai notes that the strategic shift by Aeternum Health into critical mineral mining and longevity healthcare aligns with significant global trends. The demand for critical minerals is driven by the energy transition and technological advancements, while the longevity and anti-aging market is experiencing rapid growth due to an aging global population and increasing consumer interest in healthspan optimization.

Comparison to Industry Standards

• The company's lack of revenue from continuing operations and significant operating losses are not typical for established companies in the mining or healthcare sectors, but may be expected for early-stage ventures in these fields.
• The substantial accumulated deficit and going concern warnings are common for companies undergoing significant strategic transitions or early-stage development, but would be a concern for mature, stable businesses.
• The company's focus on critical minerals places it in a sector with high capital requirements and significant geopolitical risks, where successful project development and financing are key differentiators.
• In the longevity and peptide-based therapy space, companies typically require substantial R&D investment and face long regulatory approval pathways, with success often dependent on clinical trial outcomes and intellectual property protection.

Corporate Governance

Legal Proceedings

• None

Related Party Transactions

• Notes payable due to Paul Mann totaling $2,180,348 as of June 30, 2026, including $90,000 in accrued consulting fees.
• Consulting expense of $60,000 recognized under the agreement with Paul Mann for corporate development, business strategy, and fundraising services.
• Loans from related parties totaling $2,170,000 during the six months ended June 30, 2026.
• Sales of common stock to Mr. Kim for cash proceeds totaling $18,500 to pay expenses during the period.
• Accrued officer compensation related party of $506,668 and accrued interest related party of $216,014 as of June 30, 2026.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, but also potential upside from new strategic direction. The company's ability to continue as a going concern poses a significant risk.
• Creditors: The company's going concern status and reliance on related-party funding may impact the security of their debt.
• Management: Responsible for executing the new strategy and securing necessary financing, while addressing the ineffectiveness of disclosure controls.
• Employees: The shift in business focus may lead to changes in roles and responsibilities, and job security is tied to the company's ability to secure funding and achieve operational success.

Next Steps

• Obtain additional financing through debt and equity financings, related-party funding, and other potential sources.
• Successfully execute the new business plan in critical mineral mining and longevity-focused healthcare.
• Complete the investment in American Renaissance Minerals LLC, subject to closing conditions.
• Develop the Nkamouna Nickel-Cobalt Project in Cameroon.
• Continue development of longevity and anti-aging solutions, including peptide-based therapies.

Key Dates

Recommendation

The company has undergone a significant strategic transformation, moving into potentially high-growth sectors of critical minerals and longevity healthcare. The recent merger and divestiture of the old business are positive steps. However, the substantial accumulated deficit, lack of revenue from continuing operations, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern present significant risks. The company's future hinges on its ability to secure substantial additional financing and successfully execute its new business plan. Given these uncertainties, a 'hold' recommendation is appropriate, pending further clarity on financing and operational progress.

Keywords

Aeternum Health, Merger, Critical Minerals, Longevity, Healthcare, Mining, Discontinued Operations, Going Concern